Cutaneous malignant melanoma and Parkinson disease: Common pathways?. Issue 6 (14th November 2016)

• Record Type: Journal Article
• Authors: Inzelberg, Rivka; Flash, Shira; Friedman, Eitan; Azizi, Esther
• Is Part Of: Annals of neurology. Volume 80:Issue 6(2016:Dec.)
• Page Start: 811
• Page End: 820
• Publication Date: 2016-11-14
• Subjects: Neurology -- Periodicals; Pediatric neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; 616.8
• DOI: 10.1002/ana.24802
• Languages: English
• ISSNs: 0364-5134

Abstract

Abstract : The mechanisms underlying the high prevalence of cutaneous malignant melanoma (CMM) in Parkinson disease (PD) are unclear, but plausibly involve common pathways. 129Ser‐phosphorylated α‐synuclein, a pathological PD hallmark, is abundantly expressed in CMM, but not in normal skin. In inherited PD, PARK genes harbor germline mutations; the same genes are somatically mutated in CMM, or their encoded proteins are involved in melanomagenesis. Conversely, genes associated with CMM affect PD risk. PD/CMM‐targeted cells share neural crest origin and melanogenesis capability. Pigmentation gene variants may underlie their susceptibility. We review putative genetic intersections that may be suggestive of shared pathways in neurodegeneration/melanomagenesis. Ann Neurol 2016;80:811–820